FOI 9631 – Q2

Q2. How many new patients were treated for any condition by the Trust's Rheumatology Department in the latest 3-month period of April, May and June 2026 (or the latest 3 months available) with the treatments I have provided below?

If you are able to, could you please provide the split of new patients who received their treatment for Axial Spondyloarthritis (axSpA), Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA).

IS notes: *Where volumes are 5 or less, these have been replaced with '<=5' so they are not patient identifiable*

	Total Rheumatology Department	Axial Spondyloarthritis (axSpA)	Rheumatoid Arthritis (RA)	Psoriatic Arthritis (PsA)
Abatacept [Orencia]	<=5		<=5	0
Adalimumab [Humira]	0	0	0	0
Adalimumab [All Biosimilars]	8	0	<=5	0
Apremilast [Otezla]	0			0
Apremilast [Generic]	<=5			0
Baricitinib [Olumiant]	0		0	
Bimekizumab [Bimzelx]	<=5	0		
Certolizumab [Cimzia]	0	0	0	0
Etanercept [Enbrel]	0	0	0	0
Etanercept [All Biosimilars]	0	0	0	0
Filgotinib [Jyseleca]	0		0	
Golimumab [Simponi]	0	0	0	0
Golimumab [All Biosimilars]	0	0	0	0
Guselkumab [Tremfya]	0		0	0
Infliximab [Remicade]	<=5	0	0	0
Infliximab [All Biosimilars]	<=5	<=5	<=5	0
Ixekizumab [Taltz]	0	0		0
Risankizumab [Skyrizi]	0			0
Rituximab [MabThera]	0		0	
Rituximab [Biosimilars]	6		<=5	

Sarilumab [Kevzara]	0		0	
Secukinumab [Cosentyx]	<=5	0		0
Tocilizumab [RoActemra]	0		0	
Tocilizumab [Biosimilars]	<=5		0	
Tofacitinib [Xeljanz]	0	0	0	0
Upadacitinib [Rinvoq]	<=5	0	0	0
Ustekinumab [Stelara]	0			0
Ustekinumab Biosimilar	0			0